Evolus (NASDAQ:EOLS - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $27.00 price objective on the stock. HC Wainwright's price target would indicate a potential upside of 57.53% from the stock's current price.
A number of other equities analysts have also weighed in on EOLS. Barclays boosted their target price on Evolus from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, September 13th. Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Evolus in a report on Friday, September 13th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Evolus in a research report on Monday, September 16th.
View Our Latest Analysis on EOLS
NASDAQ:EOLS opened at $17.14 on Thursday. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -16.32 and a beta of 1.31. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26. The company's 50 day moving average price is $14.85 and its 200-day moving average price is $13.21. Evolus has a 52 week low of $7.44 and a 52 week high of $17.70.
Evolus (NASDAQ:EOLS - Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to analyst estimates of $65.06 million. On average, equities research analysts forecast that Evolus will post -0.64 earnings per share for the current fiscal year.
In related news, CFO Sandra Beaver sold 3,276 shares of the business's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares of the company's stock, valued at approximately $1,305,643.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares of the company's stock, valued at $2,224,559.96. The disclosure for this sale can be found here. Company insiders own 6.10% of the company's stock.
A number of hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC boosted its holdings in Evolus by 166.8% in the 4th quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company's stock worth $41,735,000 after buying an additional 2,477,623 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Evolus by 5,627.2% in the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company's stock valued at $10,276,000 after acquiring an additional 930,566 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in shares of Evolus in the first quarter worth about $11,628,000. BNP Paribas Financial Markets grew its position in shares of Evolus by 84.2% during the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company's stock worth $5,683,000 after purchasing an additional 185,532 shares in the last quarter. Finally, Armistice Capital LLC bought a new stake in Evolus during the 2nd quarter valued at approximately $3,906,000. 90.69% of the stock is currently owned by institutional investors.
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.